Effects of atorvastatin on lipid profile and coagulation parameters

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 10, 2001, Pages 691-698

  Demir, Mesut ^a   Acartürk, Esmeray ^a   Şaşmaz, Ilgen ^a   Çayli, Murat ^a   Kilinç, Yurdanur ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Atorvastatin; Coagulation; Endothelial function

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; COUGHING; DRUG EFFECT; DRUG INDUCED DISEASE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; PRIORITY JOURNAL;

EID: 0035201357     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80076-X     Document Type: Article

References (34)

1. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease
2. Ten year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease
3. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St.Thomas' Atherosclerosis Regression Study (STARS)
4. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial
5. Endothelial control of vascular tone in large and small coronary arteries
6. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension
7. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates
8. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
10. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)
11. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia
12. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS)
13. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel II)
14. Clinical-pathological correlations of coronary disease progression and regression
15. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographic trials
16. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
17. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
18. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia
19. Haemostatic function in myocardial infarction
20. Plasma tissue plasminogen activator levels in patients with coronary heart disease
21. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
22. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients
23. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
24. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
25. Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile
26. Blood coagulation and fibrinolysis
27. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
28. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
29. Fibrinogen as a risk factor for stroke and myocardial infarction
30. Haemostatic function and ischemic heart disease: Principal results of the Northwick Park Heart Study
31. Haemostatic factors associated with ischaemic heart disease in men aged 45 to 64 years. The Speedwell Study
32. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs
33. Effect of atorvastatin on plasma fibrinogen
34. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids